In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:

• The clinical implications of using DLL3 as a therapeutic target
• The impact of emerging DLL3-targeted therapies on evolving treatment paradigms
• How to incorporate DLL3-based treatments into clinical practice

Presenters:

Daniel Morgensztern, MD
Professor of Medicine
Clinical Director of Thoracic Oncology
Washington University School of Medicine
St Louis, Missouri

Jonathan Strosberg, MD
Professor
Department of GI Oncology
Moffitt Cancer Center and Research Institute
Tampa, Florida

Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Link to full program:
https://bit.ly/4mjNPfy

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including:

• Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules
• Available pharmacodynamics/pharmacokinetics, efficacy, and safety data for subcutaneous immunotherapy formulations
• Current and potential models for administration of subcutaneous immunotherapy in the inpatient setting and day-to-day considerations

Presenters:

Kelly Romo, PharmD, BCOP
Manager, Oncology Medical Drug Management and Customer Initiatives
Blue Cross Blue Shield Michigan
Detroit, Michigan

Shawna Kraft, PharmD, BCOP
Clinical Pharmacist, Specialist
Michigan Medicine, Rogel Cancer Center
Clinical Associate Professor
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Resources:
Consolidate your learning with a recording from an on-demand webcast, download the slides associated with this discussion, or read an expert text module or commentary on this topic.

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings.

Program Abstracts:

• POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL
• ECHO: Rituximab-Bendamustine ± Acalabrutinib in Untreated High-Risk MCL
• CADANCE-101: BGB-16673 BTK Degrader in R/R CLL/SLL
• InMIND: Tafasitamab, Lenalidomide, Rituximab in R/R FL
• SHR2554: Oral EZH2 Inhibitor in R/R PTCL
• SYRUS: AZD0486 Bispecific Antibody for R/R B-ALL

Presenters:

Max S. Topp, MD
Head of Hematology and Clinical CAR-T Program Lead
Associated Professor
Medinische Klinik und Poliklinkik II
University of Wurzburg
Wurzburg, Germany

Pier Luigi Zinzani, MD, PhD
Professor of Hematology
Alma Mater Studiorum- University of Bologna
Head, “Seràgnoli” Institute of Hematology
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Department of Medical and Surgical Sciences
Bologna University School of Medicine
Bologna, Italy

Link to full program:
https://bit.ly/4obcJPI